Direct treatment costs of HIV/AIDS in Portugal

• Published in: Revista de saúde pública Vol. 47; no. 5; pp. 865 - 872
• Main Authors: Perelman, Julian, Alves, Joana, Miranda, Ana Cláudia, Mateus, Céu, Mansinho, Kamal, Antunes, Francisco, Oliveira, Joaquim, Poças, José, Doroana, Manuela, Marques, Rui, Teófilo, Eugénio, Pereira, João
• Format: Journal Article
• Language: Portuguese
• Published: Faculdade de Saúde Pública da Universidade de São Paulo 01.10.2013
• Subjects: Health Policy & Services; Anti-HIV Agents, economics; Economics, Medical; Fármacos Anti-VIH, economía; Health Care Costs; Fármacos Anti-HIV, economia; Economia Médica; Síndrome de Inmunodeficiencia Adquirida, economía; Costos de la Atención en Salud; Economía Médica; Síndrome de Imunodeficiência Adquirida, economia; Acquired Immunodeficiency Syndrome, economics; Custos de Cuidados de Saúde
• ISSN: 1518-8787
• DOI: 10.1590/S0034-8910.2013047004598

OBJECTIVE To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service. METHODS A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients’ characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals. RESULTS The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages. CONCLUSIONS The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs.